Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs
Status:
Not yet recruiting
Trial end date:
2022-07-02
Target enrollment:
Participant gender:
Summary
This study evaluates clinical responses and cost-effectiveness of using etanercept (ETN) and
conventional synthetic Disease modifying anti-rheumatic drugs (csDMARDs) with treat-to-target
strategy in ankylosing spondylitis patients. Half of participants will be used
treat-to-target strategy with ETN and csDMARDs, while the others will be used conventional
therapy scheme with ETN only.